Real Time Search
CES A80 :
CES 120 :
Total Turn.

Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

2023-09-28 10:07:00

HONG KONG, Sept. 28, 2023 /PRNewswire/ --  Akeso, Inc. (the Company, Akeso, 9926.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AK117, a next generation CD47 monoclonal antibody in combination with azacitidine for treatment of patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS). The upcoming study, known as a randomized, double-blind, global multi-center Phase II study, is set to be conducted in the United States.

Based on the favorable safety profile and remarkable efficacy of AK117 in combination with azacitidine for the treatment of newly diagnosed higher-risk MDS patients, as showcased in previous studies, and the strong demand from MDS patients worldwide, Akeso has conducted comprehensive scientific communication and discussions with the FDA. Akeso believes that this study will facilitate the global development process for AK117.

"With more time and space, we will consistently implement a comprehensive international strategy to explore and advance our innovative therapies. For the benefit of more patients, we will leverage global resources to improve the success rate of AK117." Said Dr. Michelle Xia, the founder, Chairwoman, CEO, and President of Akeso.

Anemia is a significant symptom of MDS, and effectively managing anemia and minimizing blood transfusion are crucial aspects of disease control. In contrast to other anti-CD47 antibody drugs, which have been reported to worsen anemia in MDS patients by causing RBC hemagglutination, AK117 eliminated RBC hemagglutination and also enabled to maintain full effectiveness of CD47 blockade on tumor cells, which resulted in excellent antitumor efficacy and favorable safety profile of AK117.

The previous studies of AK117 in combination with azacitidine showed positive results in patients with newly diagnosed higher-risk MDS. AK117 reduced anemia and transfusion requirements among MDS patients, and demonstrated a favorable safety profile and remarkable efficacy. These findings position AK117 as a promising therapeutic option for MDS patients worldwide.

Notably, Akeso is consistently advancing the development of AK117 as a therapeutic agent in combination with various agents such as PD-1/CTLA-4 and PD-1/VEGF, for treatment of multiple hematologic malignancies and solid tumors.

About Ligufalimab (AK117)

AK117, independently developed by Akeso, is a next generation of humanized lgG4 anti-CD47 antibody without hemagglutination effect. AK117 can bind to CD47 expressed on tumor cells and block the interaction between CD47 and SIRPα, in order to enhance the phagocytic activity of phagocytes on tumor cells, thereby inhibiting the growth of tumors.


PR Newswire News

Brinc Introduces New Partners & Collaborators for 2024 Web3 & Gaming Programs
Inaugural Asia FII PRIORITY Summit Powered By FII Institute To Take Place In Hong Kong On 7 & 8 December
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
N mobile Makes Its Disruptive Debut - Probably the best value travel & lifestyle mobile brand in Hong Kong
Kai Tin Shopping Centre Unveils Its New Wing with an Exciting New Look and New Shops
The Grand Opening of River Cam Dermatology Centre and River Cam Nutrition Center (Shatin) Amalgamates Ancient Chinese Medicine Skin Care Wisdom and Nutrition Science
First Digital's Stablecoin FDUSD Hits US$1 Billion Market Cap on Strong Market Adoption
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment
The 2023 Investor Open Day of Zylox-Tonbridge was successfully held
inQB8 Medical Technologies LLC and Peijia Medical Limited Report Successful First-in-Human (FIH) Implantation of MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System in The United States of America
Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
MINISO Group Responded to Unusual Price and Trading Volume Movements and Increase Plan in Shareholding by Managements
Sun Hung Kai Properties' flagship project TOWNPLACE WEST KOWLOON unveils 53,000-sq. ft. TP SOCIAL CLUB, showcasing the "Bleisure Lifestyle"
Reimagining education: 2023 Yidan Prize Summit explores innovative ideas that spark change
SUNeVision Partners with Digital Edge to Fast-track Customers' Regional Expansion
CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck
Govee Partners with Warner Bros. for "Aquaman and the Lost Kingdom" to Bring an Immersive Lighting Experience to Fans
Back to Top